Disturbed Glucocorticoid Receptor Autoregulation and Corticotropin Response to Dexamethasone in Depressives Pretreated With Metyrapone

Rainer Rupprecht, Johannes Kornhuber, Norbert Wodarz, Johannes Lugauer, Claudia Göbel, Doris Haack, Georg Beck, Otto-Albrecht Müller, Peter Riederer, and Helmut Beckmann

We studied glucocorticoid receptor autoregulation and corticotropin response to dexamethasone in depressed patients and controls, attempting to control for the confounding effect of endogenous glucocorticoids. After depletion of endogenous cortisol, depressed patients showed an attenuated suppressibility of corticotropin by dexamethasone in the face of unchanged dexamethasone plasma levels. β-endorphin levels were strongly correlated with adrenocorticotropic hormone (ACTH) concentrations. Although metyrapone administration resulted in a marked rise of glucocorticoid receptor sites per cell in controls, this effect was not present in depressives. These data support the hypothesis of a decreased glucocorticoid receptor plasticity and a partial steroid resistance in depression.

Introduction

Abnormalities of hypothalamic–pituitary–adrenal (HPA) system integrity linked to depression include 24-hr hypersecretion of cortisol during depressive episodes (Linkowski et al 1985, 1987), inadequate suppressibility of cortisol by dexamethasone (Carroll et al 1968), and hyperresponsiveness of the adrenal cortex to exogenous corticotropin [adrenocorticotropic hormone (ACTH)] (Amsterdam et al 1984). Moreover, hypersecretion of corticotropin-releasing hormone (CRH) has been detected in the cerebrospinal fluid of depressed patients (Nemeroff et al 1984). Studies on the application of ovine (Gold et al 1984, 1986) and human (Holsboer et al 1984a, 1987; Rupprecht et al 1989a) CRH in depression have shown an attenuated response of ACTH in depressed patients, possibly related to hypercortisolemia (Gold et al 1986). However, recent investigations were unable to reproduce the blunted ACTH response to CRH in depression, when cortisol synthesis was previously blocked with the 11-β-hydroxylase inhibitor metyrapone (MET) (von
Bardeleben et al 1988; Lisansky et al 1989). Instead, even an augmented ACTH response to CRH has been noted in depressives after equalizing the amount of the glucocorticoid-mediated feedback in all subjects (Lisansky et al 1989).

An escape of plasma ACTH (Fang et al 1981) and β-endorphin (Matthews et al 1986, Rupprecht et al 1988) from dexamethasone suppression in endogenously depressed patients provided evidence of a subtle derangement of the feedback regulation of the HPA system during depression. Moreover, reports of an inadequate suppression of prolactin (Meltzer et al 1982; Klein et al 1984; Rupprecht et al 1987) and thyroid-stimulating hormone (TSH) (Rupprecht et al 1989c) as well as an augmented response of the hypothalamic–pituitary–somatotropic (HPS) system (Rupprecht et al 1989b) following glucocorticoid administration in depression have supported the idea that the derangement of the glucocorticoid-mediated negative feedback is not only restricted to the HPA system but involves a variety of neuroendocrine systems. In addition, dexamethasone bioavailability has been shown to be lower in depressed patients with positive dexamethasone suppression test (DST) (Holsboer et al 1984b; Lowy and Meltzer 1987; Holsboer et al 1986), resulting in a shortened dexamethasone half-life in DST nonsuppressors due to an enhanced elimination of the test drug (Holsboer et al 1986).

Several authors have investigated the potential role of glucocorticoid receptors (GR) in this context, with considerably different results. Some reports noted lower GR sites per cell in depressed patients (Gormley et al 1985; Whalley et al 1986), whereas others found a reduced downregulation of GR concentrations only in DST nonsuppressors (Lowy et al 1988) or failed to detect differences between depressed patients and controls or between DST nonsuppressors and suppressors (Schlechte and Sherman 1985).

Hypercortisolemia in depression represents a major confounding factor in accurate assessment of the HPA system and its feedback mechanism. The present study, designed to determine the effect of dexamethasone (DEX) administered in vivo on ACTH and β-endorphin levels in relation to DEX plasma concentrations and GR autoregulation, avoided the potential effects of hypercortisolemia by metyrapone (MET)-induced blockage of cortisol synthesis.

Subjects and Methods

Subjects

The patient group comprised 5 men and 13 women with unipolar major depressive disorder or bipolar depression aged between 18 and 72 years (mean ± SD, 50.0 ± 15.1 years), with a mean (± SD) body weight of 73.8 ± 13.7 kg. The control group comprised 2 men and 12 women aged between 33 and 57 years (mean ± SD, 47.1 ± 7.2 years), with a mean (± SD) body weight of 68.4 ± 10.1 kg. All subjects were carefully screened for prevalence of medical illness that might influence pituitary–adrenal function by medical history, physical examination, and routine laboratory tests. Six female depressives and five female controls were tested during the midluteal phase of the cycle; the other women were postmenopausal. DSM-III-R (American Psychiatric Association 1987) diagnoses were made on all patients by the consensus of two psychiatrists, who were blind to laboratory results. Severity of depression was assessed by the 21-item Hamilton Rating Scale for Depression (HRSD) (Hamilton 1960). The mean (± SD) HRSD score of the patients was 27.2 ± 4.6, ranging from 18 to 36. Patients were studied after a drug-free period of at least 72 hr. Details on clinical and demographic data of the patients and the medication given before the drug-free interval are shown in Table 1.
Table 1. Demographic Data, Antidepressants Prior to the Washout Period, and Diagnostic Description of the Depressed Patients

<table>
<thead>
<tr>
<th>Patient no.</th>
<th>Age (yr)/sex</th>
<th>DSM-III-R</th>
<th>Drug-free period (d)</th>
<th>Treatment before drug-free period</th>
<th>Depressive episodes</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>44/F</td>
<td>Bipolar disorder, depressed</td>
<td>33</td>
<td>&gt;28</td>
<td>3</td>
</tr>
<tr>
<td>2</td>
<td>66/F</td>
<td>MDD, recurrent, with melancholia</td>
<td>36</td>
<td>&gt;28</td>
<td>2</td>
</tr>
<tr>
<td>3</td>
<td>61/F</td>
<td>MDD, recurrent, with melancholia, mood congruent psychotic</td>
<td>28</td>
<td>&gt;28</td>
<td>3</td>
</tr>
<tr>
<td>4</td>
<td>64/F</td>
<td>MDD, recurrent, with melancholia</td>
<td>28</td>
<td>&gt;28</td>
<td>4</td>
</tr>
<tr>
<td>5</td>
<td>39/F</td>
<td>MDD, recurrent</td>
<td>25</td>
<td>7</td>
<td>Amitryptiline 100 mg</td>
</tr>
<tr>
<td>6</td>
<td>60/M</td>
<td>MDD, recurrent, with melancholia</td>
<td>24</td>
<td>5</td>
<td>Amitryptiline 100 mg</td>
</tr>
<tr>
<td>7</td>
<td>60/M</td>
<td>MDD, recurrent, with melancholia</td>
<td>28</td>
<td>5</td>
<td>Maprotiline 150 mg</td>
</tr>
<tr>
<td>8</td>
<td>34/F</td>
<td>MDD, recurrent, with melancholia</td>
<td>28</td>
<td>4</td>
<td>Maprotiline 100 mg</td>
</tr>
<tr>
<td>9</td>
<td>49/M</td>
<td>MDD, single episode</td>
<td>21</td>
<td>7</td>
<td>Maprotiline 100 mg</td>
</tr>
<tr>
<td>10</td>
<td>31/F</td>
<td>Bipolar disorder, depressed</td>
<td>18</td>
<td>4</td>
<td>Lorazepam 3 mg</td>
</tr>
<tr>
<td>11</td>
<td>55/F</td>
<td>MDD, recurrent, with melancholia</td>
<td>26</td>
<td>5</td>
<td>Maprotiline 150 mg</td>
</tr>
<tr>
<td>12</td>
<td>26/F</td>
<td>MDD, single episode with melancholia</td>
<td>26</td>
<td>4</td>
<td>Amitryptiline 75 mg</td>
</tr>
<tr>
<td>13</td>
<td>60/M</td>
<td>Bipolar disorder, depressed</td>
<td>30</td>
<td>6</td>
<td>Clomipramine 150 mg</td>
</tr>
<tr>
<td>14</td>
<td>57/F</td>
<td>MDD, recurrent, with melancholia, mood congruent psychotic</td>
<td>31</td>
<td>5</td>
<td>Maprotiline 150 mg</td>
</tr>
<tr>
<td>15</td>
<td>72/F</td>
<td>MDD, recurrent</td>
<td>29</td>
<td>5</td>
<td>Amitryptiline 150 mg</td>
</tr>
<tr>
<td>16</td>
<td>54/F</td>
<td>Bipolar disorder, depressed</td>
<td>33</td>
<td>&gt;28</td>
<td>6</td>
</tr>
<tr>
<td>17</td>
<td>18/F</td>
<td>MDD, single episode</td>
<td>26</td>
<td>&gt;28</td>
<td>1</td>
</tr>
<tr>
<td>18</td>
<td>53/M</td>
<td>MDD, recurrent</td>
<td>26</td>
<td>&gt;21</td>
<td>2</td>
</tr>
</tbody>
</table>

Controls had no history of psychiatric disorder and were medication free for at least 4 weeks.

**Study Design**

After the nature of the study had been fully explained, written informed consent was obtained from patients and controls. The test protocol was approved by the ethics committee of the University of Würzburg and the requirements of the revised version of the Helsinki Declaration were strictly followed. All subjects were admitted to a sleep laboratory unit at least 1 hr prior to drug administration or blood sampling.

For determination of GR binding characteristics and hormone data 50 ml blood were collected at 4 PM into prechilled plastic tubes containing EDTA on three consecutive days. On day 1, baseline values were obtained. On day 2, the subjects were pretreated with 1.5 g MET at 9 AM administered orally with milk to avoid severe gastric symptoms. One milligram DEX was given orally at 11 PM. On day 3, administration of 1.5 g MET was given as described for day 2. The study design is summarized in Table 2. Eighty percent of the subjects experienced a transient dizziness and a hot flush after MET administration, which disappeared spontaneously within 45–60 min.

**Assays**

*Glucocorticoid Receptor Assay.* GR pharmacological characteristics were determined as described in detail elsewhere (Rupprecht et al 1990). A mononuclear cell fraction was prepared by sodium metrizoate-Ficoll density gradient centrifugation (Boyum 1968). Cells
were washed two times in phosphate-buffered saline (PBS) for 10 min, incubated for 60 min at 37°C to allow sufficient dissociation of endogenous hormone, and then washed again. The final concentration of cells was determined using a Coulter Counter (Model S5, Coulter Electronics Ltd, England). Viability of cells exceeded 95%, as judged from their ability to exclude trypan blue. Contamination by erythrocytes was less than 10%, and contamination by granulocytes and monocytes was less than 8% and did not differ among the three test days or between patients and controls.

Binding experiments were carried out at 37°C in plastic microtiter plates in a total volume of 0.25 ml using 106 cells per well. The displacing compound (final concentration 10 μmol/L unlabeled dexamethasone) was added immediately prior to the addition of [3H]dexamethasone (specific activity 84 Ci/mmol) to determine nonspecific binding. Saturation experiments were performed on each blood sample using increasing concentrations of [3H]dexamethasone from 1 to 40 nmol/L. Saturation experiments were performed at equilibrium after a 90-min incubation period. After incubation, bound ligand was separated from free ligand by rapid filtration through Scatron filters with a Titertek cell harvester (Scatron, England) by washing with PBS (pH = 7.4) at room temperature. The filters were transferred into plastic vials, 5 ml of a toluene-based scintillation cocktail was added, and they were monitored for tritium in a Beckman LS 1801 counter at about 54% efficiency. All samples were assayed in triplicate with a variation within a single experiment of less than 7%. The interassay variability was 7%.

Hormone Assays. ACTH was measured by an IRMA supplied by the Nichols Institute (San Juan Capistrano, CA), which does not require extraction procedures (Raff and Findling 1989). A soluble sandwich complex is formed by a 125I-labeled monoclonal antibody directed against N-terminal ACTH and a biotin-coupled polyclonal antibody against C-terminal ACTH. The sandwich complexes are bound by adding avidin-coated plastic bead. Unbound components are washed away and the radioactivity bound to the solid phase is monitored in a gamma counter. The lower detection limit was 1.5 pmol/L, and the intraassay and interassay coefficients of variation were 3% and 6.8%, respectively. Values below the detection limit were recorded as 1.5 pmol/L.

β-Endorphin was determined by radioimmunoassay (RIA) (ImmunoNuclear Corp, Stillwater, MN) after extraction with anti-β-endorphin antibodies coupled to Sepharose (Rupprecht et al 1988, 1989a). The minimal detectable concentration was 1.5 pmol/L, and the intraassay and interassay coefficients of variation were 6% and 8%, respectively.

Cortisol was measured by a direct RIA (Stalla et al 1981). The lower detection limit was 25 nmol/L, and the intraassay and interassay coefficients of variation were 5% and 9%, respectively. As there was a cross-reactivity of our cortisol antibody with 11-deoxycortisol of about 15%, determinations of cortisol values following MET administration would not be accurate and were excluded from further analysis.

11-Deoxycortisol (11-DOC) was determined by a radioimmunologic method described
previously (Vecsei 1981). 11-DOC was extracted from plasma using ethylglycole and assayed directly using an antibody raised against the C-3-oxime of the steroid. The lower detection limit was 1.5 nmol/L. The recovery was about 80%, and the intraassay and interassay coefficients of variation were 5% and 13%, respectively. Cross-reactivities were 1.5% with cortisol and 0.2% with DEX. DEX was measured in unprocessed plasma using a direct RIA method with antibodies raised against the C-3-oxime of DEX as described in detail elsewhere (Haack et al 1981).

The lower detection limit was 0.5 nmol/L. The intraassay and interassay variations were 6.7% and 14.7%, respectively.

Data Analysis

Preliminary estimates of binding parameters from saturation experiments were provided by the EBDA program (McPershon 1983). Final estimates of binding parameters were determined with a computerized nonlinear, least-square regression analysis (Munson and Rodbard 1980). This weighted curve fitting program assumes binding according to the law of mass action to independent classes of binding sites. The results are expressed as the mean ± SD, and as the mean ± SE in Figures 1–5.

Differences in receptor and hormone data within subjects were analyzed by analysis of variance (ANOVA) for repeated measurements. Differences between patients and controls and between depressive subgroups were analyzed by ANOVA followed by post hoc comparisons with Student’s t-test. Additionally, the ANOVA was repeated with the cofactors age, HRSD score, and cortisol, ACTH, 11-DOC, and DEX concentrations. Contingency tables were analyzed by χ² analysis with Yates correction. Correlation data were obtained by Pearson’s product moment correlation. All significance levels are two-tailed.

Results

Administration of MET resulted in a sufficient blockade of the 11-β-hydroxylase, as shown by the excessive rise in 11-DOC (Figure 1) (p < 0.001), ACTH (Figure 2) (p < 0.001), and β-endorphin (Figure 3) (p < 0.001) in patients and controls, which was avoided by DEX pretreatment. Baseline cortisol values at 4 PM did not differ significantly
between patients (mean ± SD, 253.1 ± 115.7 nmol/L) and controls (mean ± SD, 218.0 ± 74.5 nmol/L). Although 11-DOC concentrations did not differ between patients and controls under either test condition, depressed patients exhibited slightly higher ACTH concentrations after MET + DEX pretreatment (p < 0.05) (Figure 2). The corresponding β-endorphin values just failed to reach statistical significance (p < 0.07). ACTH and β-endorphin values were strongly correlated in the patient and control group as well as in both groups combined (r = 0.8, p < 0.001). Dexamethasone plasma levels were similar in depressives (mean ± SD, 2.72 ± 0.25 nmol/L) and controls (2.47 ± 0.22 nmol/L).

Of the 14 controls, 13 showed complete suppression of ACTH below the detection limit of the assay of ≤ 5 pmol/L following DEX administration (“ACTH suppressors”). In contrast, only 8 of 18 patients were able to suppress ACTH completely, whereas the remaining 10 patients had postdexamethasone ACTH levels ranging from 2.6 to 8.6 pmol/L (“ACTH nonsuppressors”). χ² analysis with Yates correction indicated a significantly greater proportion of “ACTH nonsuppressors” among the patients (p < 0.02). Surprisingly, there was no difference in DEX plasma concentrations between ACTH nonsuppressors (mean ± SD, 2.32 ± 0.87 nmol/L) and suppressors (mean ± SD, 2.74 ± 0.90 nmol/L), while baseline cortisol values were significantly higher in ACTH non-
Glucocorticoid Receptors in Depression

suppressors (mean ± SD, 294.8 ± 124.8 versus 206.5 ± 72.4 nmol/L) (p < 0.05). There was no relationship among age, sex, HRSD score, depressive subtype, number of depressive episodes, length of previous episode, length of the washout period, or treatment prior to the washout period and cortisol, ACTH, or β-endorphin concentration.

To determine the effects of baseline cortisol levels and ACTH, 11-DOC, and DEX plasma concentrations on GR binding characteristics in relation to diagnostic group as main effect, these factors were included as covariates in the ANOVA model for diagnostic group. With these covariates entered to allow for their maximum contribution, depressed patients had significantly fewer GR sites per cell (p < 0.005) (Figure 4) and a lower $K_d$ (p < 0.04) (Figure 5) following MET administration when compared with controls. The covariates did not contribute significantly to the explanation of the variance. No significant difference could be observed with regard to baseline and MET + DEX pretreated test conditions. There was an inverse relationship between baseline cortisol and baseline GR sites per cell in the whole sample ($r = -0.63, p < 0.001$) and in the patient group ($r = -0.72; p < 0.01$) but not within the control group ($r = 0.51, NS$). GR binding parameters did not correlate with ACTH, β-endorphin, 11-DOC, or DEX concentrations under either test condition. Moreover, the clinical features mentioned above showed no

Figure 4. Mean ± SE glucocorticoid receptor sites per cell in depressed patients (solid bars, $n = 15$) and normal controls (shaded bars, $n = 18$). The asterisk indicates a significant difference ($p < 0.005$).

Figure 5. Mean ± SE $K_d$ in depressed patients (solid bars, $n = 18$) and normal controls (shaded bars, $n = 14$). The asterisk indicates a significant difference ($p < 0.04$).
association with GR paradigms. There were no differences between patients drug free for more than 21 days, and those with a shorter washout period with regard to hormone or GR data.

Discussion

Although a variety of studies (Arana et al 1985) have replicated the frequently occurring attenuated response of cortisol to DEX in patients with major depressive disorder, the pathophysiology of DST nonsuppression remains still unsolved. It has been suggested that the positive DST reflects hypercortisolemia (Poland et al 1987), and studies on DEX pharmacokinetics have shown a decreased bioavailability in depressed DST nonsuppressors (Lowy and Meltzer 1987; Holsboer et al 1986) due to a shortened half-life of the test drug (Holsboer et al 1986). Thus, the metabolism of DEX may contribute to positive DST results. However, even if DEX plasma levels were covaried out, the degree of DST nonsuppression in depression would not be fully explained by DEX bioavailability (Poland et al 1987).

The endocrine effects of cortisol and DEX are mediated via the mineralocorticoid receptor (MR) (type I) in the hippocampus and preferentially via the GR (type II) in the hippocampus, the hypothalamus, and the pituitary (Arriza et al 1987; De Kloet and Reul 1987). We therefore investigated whether the response of the HPA system to DEX as a reflection of GR function in vivo is still attenuated in depressed patients after eliminating by MET the competition of DEX with elevated endogenous cortisol in relation to DEX plasma concentrations. Although we did not find a significant elevation of 4 pm baseline cortisol, this does not exclude hypercortisolemia, since it was only a single point measurement and the HPA axis is relatively quiescent at this time (Amsterdam et al 1987). Further studies should apply a multiple time point measurement to detect eventual shifts in the rhythm of ACTH or cortisol. There was an attenuated response of ACTH to DEX in depressives, with a significantly greater proportion of patients than controls with incomplete suppression of ACTH by DEX. These data show that the impaired response of ACTH and β-endorphin in endogenous depression previously described under baseline conditions (Fang et al 1981; Matthews et al 1986; Rupprecht et al 1988) still persists after depletion of endogenous cortisol. The attenuated response of ACTH to DEX independent of hypercortisolemia and DEX bioavailability in depression lends support to the idea of a defect of GR function in vivo, as has been suggested by reports of an impaired response also of prolactin (Meltzer et al 1982; Rupprecht et al 1987) and TSH (Rupprecht et al 1989c) to DEX in depression.

Our study of baseline GR binding characteristics did not reveal any difference between depressed patients and controls or between ACTH nonsuppressors and suppressors. These findings confirm previous investigations (Schlechte and Sherman 1985) and suggest that the GR is not downregulated by hypercortisolemia in depression. However, other groups have reported lower GR sites in depression (Gormley et al 1985; Whalley et al 1986). Although GR has been reported to be under autoregulatory control in animals (Reul et al 1987) and humans (Rupprecht et al 1990), the patients showed no changes of GR binding characteristics related to major shifts of glucocorticoid levels whereas the controls responded to depletion of endogenous cortisol with a marked rise in GR sites per cell. Thus, the inverse relation of GR sites and cortisol levels in depressives but not in controls reflects steroid resistance rather than GR downregulation. This is further supported by the absence of clinical features of a Cushing’s syndrome despite the remarkable hyper-
cortisolemia noted in some of the depressive patients (Gormley et al 1985). The decrease in GR affinity (increase in $K_d$) in controls probably reflects a competition of the MET-induced excess in 11-DOC with labeled DEX because high amounts of 11-DOC can also bind to GRs (De Kloet and Reul 1987) without affecting the estimation of GR sites per cell (Rupprecht et al 1990). The lack of this effect in depressives also points to steroid resistance.

However, GR binding data did not correlate with the effect of DEX on ACTH secretion. It is important in this context that the response of the HPA system to DEX is mediated via GR sites in the hippocampus, the hypothalamus, and the pituitary. The hippocampal GR has been shown to underlie a more sensitive autoregulation than other brain regions (McEwen et al 1987). Although recent investigations showed a certain parallelism in the response to reserpine of the GR in the hippocampus and in leukocytes of rats (Lowy 1990), the extrapolation from the measurement of peripheral GR regulation to central nervous GR regulation should only be made with caution.

Hypercortisolemia in depression represents a major confounding factor in the assessment of the HPA system and in neurotransmitter studies by action via the GR, since immunocytochemical procedures with monoclonal antibodies (Fuxe et al 1985) have shown GRs to be present in almost all brain regions, with relatively high concentrations in the hippocampus and the hypothalamus. After this effect is controlled for by depletion of endogenous cortisol with MET, our data suggest a decrease in GR plasticity with a partial steroid resistance in vitro and in vivo in depressive patients. Monoclonal antibodies (Fuxe et al 1985) and cDNA (Okret et al 1986; Dong et al 1988) or cRNA (Kalinyak et al 1989) probes are promising tools for further elucidating the deficiency of the GR and the derangement of the HPA system in depression.

References


Glucocorticoid Receptors in Depression


Okret S, Poellinger L, Dong Y, Gustafsson JA (1986): Downregulation of glucocorticoid receptor mRNA by glucocorticoid hormones and recognition by the receptor of a specific sequence within a receptor cDNA clone. Proc Natl Acad Sci USA 83:5899-5903.


